COMP <GO>
CORT vs MRK // REVENUE GROWTH (YOY)
Corcept Therapeutics Incorporated (NASDAQ) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: CORT 5
— MRK 10
▲ REVENUE GROWTH (YOY) LEADER: CORT
LAST: $81.12 (-5.62%) • MKT CAP: $9.29B
revenue-growth
12.80%
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
revenue-growth
1.30%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CORT VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CORT | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 96.00% | 74.80% | +21.20 | CORT | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 4.80% | 20.70% | -15.90 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | 95.0x | 15.3x | +79.70 | MRK | /valuation <GO> |
| Free Cash Flow Yield | 1.53% | 3.42% | -1.89 | MRK | /fcf-yield <GO> |
| Operating Margin | 5.90% | 34.30% | -28.40 | MRK | /operating-margins <GO> |
| Net Profit Margin | 13.10% | 28.10% | -15.00 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 12.80% | 1.30% | +11.50 | CORT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 5.19 | +20.81 | CORT | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | CORT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.50% | 6.60% | -0.10 | CORT | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 23.1 | 56.9 | -33.72 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.88 | 0.92 | -0.04 | MRK | /macro-sensitivity <GO> |
| Forward P/E Multiple | 78.3x | 18.4x | +59.90 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $9.29B | $361.02B | -$351.73B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CORT REV | MRK REV | CORT GROSS % | MRK GROSS % | CORT FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $761.4M | $65.01B | 98.3% | 74.8% | $141.8M | $12.36B |
| FY 2024 | $675.0M | $64.17B | 98.4% | 76.3% | $196.1M | $18.10B |
| FY 2023 | $482.4M | $60.12B | 44.0% | 44.0% | $105.0M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CORT // BETA 0.88
MRK // BETA 0.92